Respiratory syncytial virus (RSV) is a major cause respiratory disease, worldwide. Paediatric and elderly populations are most vulnerable to severe disease. Vaccine development has been hampered by the experience of vaccine-enhanced disease. Animal models do not necessarily predict vaccine efficacy and safety. The strengths and limitations of animal models of RSV infection are summarised.